FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein that acts as a glutamate carboxypeptidase enzyme [5, 6] and is a useful target for diagnostic and therapeutic applications in nuclear medicine because of its’ high expression in prostate cancer cells.